AllPennyStocks.com SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals

J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.

Other Penny Stock Movers

This Critical Minerals Explorer Just Found Where to Look Next
Maiden Drill Campaign at Onuki Zone Concludes Under Sumitomo Earn-In
High-Grade 190 g/t Gold Grab Sample Highlights Manitoba Quartz Vein Expansion
Most Popular
{{ index + 1 }}


Back to Top